3 completed, 2 active not recruiting, 2 not yet recruiting, 1 recruiting. 5 Phase 4, 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Active not recruiting 2, Completed 1, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 2 | Not yet recruiting 1, Unknown 1 |
| Not applicable | 1 | Recruiting 1 |
Follow SGLT2i: new trials by email Literature Review of SGLT2i trials Research Report on SGLT2i
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SGLT2i Effect on PTDM Development and Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial SGLT2i, Placebo - Kidney Transplant Recipient, Sodium Glucose Co-Transporter 2 Inhibitors | Phase 2 | Not yet recruiting | Odense University Hospital | 184 | 2026-09-01 | 2026-07-02 |
| Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease Dulaglutide, SGLT2i, Finerenone - T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease | Phase 4 | Not yet recruiting | First Affiliated Hospital of Wannan Medical College | 468 | 2026-05-01 | 2026-04-22 |
| Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients. Dapagliflozin - End Stage Chronic Renal Failure | Not applicable | Recruiting | Oman Ministry of Health | 38 | 2026-04-01 | 2026-03-24 |
| Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen Tension JARDIANCE 25mg, Placebo - Kidney Transplantation Recipients, Magnetic Resonance Imaging (MRI) | Phase 4 | Active not recruiting | Odense University Hospital | 8 | 2025-03-27 | 2025-07-31 |
| Impact of SGLT2 Inhibitors in Heart Transplant Recipients SGLT2i - Transplant; Failure, Heart, Cardiac Allograft Vasculopathy | Phase 2 | Unknown | Universidade Federal do Ceara | 80 | 2023-11-20 | 2024-05-07 |
| proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2 Dapagliflozin 10 MG Oral Tablet [Farxiga], Placebo - Acute Kidney Injury, Cardiac Surgery | Phase 4 | Active not recruiting | Amsterdam UMC | 784 | 2023-06-09 | 2025-05-18 |
| The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure SGLT2i, No SGLT2i - Acute Decompensated Heart Failure | Phase 4 | Terminated | University of Chicago | 1 | 2023-05-22 | 2024-09-04 |
| HF Patients With LVADs Being Treated With SGLT2i SGLT2i, No SGLT2i - Heart Failure With Reduced Ejection Fraction | Phase 4 | Completed | University of Chicago | 32 | 2022-09-08 | 2026-06-03 |
| Comparison of Type 2 Diabetes Pharmacotherapy Regimens SU, DPP4, SGLT2i - Type 2 Diabetes Mellitus, Cardiovascular Diseases | Completed | Kaiser Permanente | 241981 | 2021-07-01 | 2025-11-21 | |
| Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity GLP-1RA, SGLT2i, Insulin - Type 2 Diabetes, Obesity | Completed | Ana Palanca | 26944 | 2014-01-01 | 2022-09-28 |
Diabetes Mellitus, Type 2 (3) · Renal Insufficiency, Chronic (2) · Acute Kidney Injury (1) · Cardiovascular Diseases (1) · Obesity (1) · Rejection, Psychology (1)
Odense University Hospital (2) · University of Chicago (2) · Amsterdam UMC (1) · Ana Palanca (1) · First Affiliated Hospital of Wannan Medical College (1) · Kaiser Permanente (1) · Oman Ministry of Health (1) · Universidade Federal do Ceara (1)
United States (3) · Denmark (2) · Brazil (1) · Netherlands (1) · Oman (1) · Spain (1)
Lotte B Lange, MD (2) · Jonathan Grinstein, MD (1) · Mark Belkin, MD (1) · Patrick J O'Connor, MD, MA, MPH (1) · Romain S. Neugebauer, PhD (1)
PMID 36847952, PMID 38745886, PMID 40153894, PMID 40379310, PMID 40734551, PMID 41091469, PMID 41462489, PMID 42530910